ACHE and Alzheimer disease: The same analysis was executed with an inactive analogue(compound 2, 2β, 3α-dihydroxy-5α-cholestan-6-one).Our first computational results showed no differences in affinityto AChE between both steroids, making further analysis necessary.This work highlights the variables to be considered and develops arefined methodology, for the successful design of new potent dual-actiondrugs for AD, particularly PAS inhibitors, an attractive strategyto combat AD.